Open-label study to evaluate the tolerability, safety and efficacy of the equimolar conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) in patients with renal transplant
Latest Information Update: 10 Feb 2011
Price :
$35 *
At a glance
- Drugs Mycophenolate sodium (Primary) ; Mycophenolate mofetil
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Novartis
- 01 Feb 2011 Actual end date (Jun 2005) added as reported by ClinicalTrials.gov.
- 01 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Dec 2005 New trial record.